Abbott Vascular appears in FDA device records as the applicant for PMA P110019, a premarket approval covering everolimus-eluting coronary stent systems. The two linked records in this collection are both PMA entries: an original approval and a later 30-day notice supplement. The filings identify the applicant at 3200 Lakeside Drive, Santa Clara, California, which is a filing address rather than a verified corporate headquarters. Product names, product code and advisory committee details come directly from the FDA records. [1][2][9]
Documented product family
The original approval record names the Xience Skypoint Everolimus Eluting Coronary Stent System under PMA P110019, product code NIQ, generic name coronary drug-eluting stent, device class 3, with the Cardiovascular advisory committee. The approval statement in that record describes the device as intended to improve coronary luminal diameter in patients with symptomatic heart disease from de novo native coronary artery lesions within stated lesion length and reference vessel diameter ranges. [2]
A later summary of safety and effectiveness data for P110019/S115 lists three trade names under the same product code: XIENCE Alpine, XIENCE Sierra and XIENCE Skypoint Everolimus Eluting Coronary Stent Systems. That document gives the applicant as Abbott Vascular, 3200 Lakeside Drive, Santa Clara, California 95054, and states that the applicant's manufacturing facilities were inspected and found compliant with the Quality System regulation at 21 CFR 820. [9]
Dated filing examples
P110019 was received on 20 April 2011 and approved on 1 November 2011, with a Federal Register notice date of 4 November 2011 and docket number 11M-0796. The record shows no expedited review flag and no supplement type or number. [2]
Supplement P110019/S145 was received on 1 September 2026 and decided on 1 October 2026 under decision code OK30. FDA classifies it as a 30-day notice with supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the applicant's statement references an automated packaging process. The trade name field lists XIENCE PRO5 Everolimus Eluting Coronary Stent System and XIENCE Skypoint Everolimus Eluting Coronary Stent System. [1]
What the collection shows
The collection contains two linked records, both on the PMA pathway. Across the full collection, decision counts are one OK30 and one APPR. The smaller record sample of two entries shows the same split of one OK30 and one APPR. These counts describe only the records retrieved as of 20 November 2026 and are not measures of total portfolio size, sales or safety performance. [1][2]
No recall records appear in the retrieved sample. The manufacturer's own XIENCE Skypoint ordering page describes the stent as having the broadest size matrix of any XIENCE stent and as the first and only drug-eluting stent approved for vessels larger than 5.0 mm; those statements are the manufacturer's published claims, not FDA findings in these records. [6]
Identity and attribution
Abbott Vascular is identified here as the FDA legal applicant on the cited PMA records. The XIENCE product names are trademarks described on Abbott's site as owned by or licensed to Abbott, its subsidiaries or affiliates. No parent, brand or ownership relationship beyond the applicant name is verified in these records. [1][2][6]


